Merck Hosts 2019 Investor Day Outlining Bus. Momentum, Strong Expected Growth & Focus on Innovative Research & Development
20 Juin 2019 - 12:45PM
Business Wire
- Momentum Across Key Pillars Expected to Drive Strong Revenue
Growth Every Year Over the Next Five Years, Including 2023 – the
Year of Greatest Anticipated Impact of JANUVIA® (sitagliptin) Loss
of Exclusivity (LOE)
- Meaningful Operating Margin Expansion Expected, Driven by
Disciplined Expense Management and Operating Model Evolution
- Broad Mid-to-Late Stage Pipeline Opportunities in Areas of
Significant Unmet Medical Need to Drive Leadership Over the Next
Decade, Including the Potential for More Than 50 New Indications in
Oncology Over the Next Five Years
- Reinvigorated Early Pipeline Efforts Spanning a Diverse Set of
Disease Areas to Deliver Important Medical Advances
At a meeting with the investment community today, Merck (NYSE:
MRK), known as MSD outside the United States and Canada, will
outline how its science-led strategy and broad pipeline of
promising transformative therapies and vaccines will position the
company to deliver strong growth and shareholder value over the
long term.
“Merck is very well positioned to pursue its mission to save and
improve lives,” said Kenneth C. Frazier, Merck chairman and chief
executive officer. “Over the last five years, we have revitalized
our focus on research in order to invent, develop and commercialize
valuable and innovative medicines and vaccines that address many of
the world’s most pressing health challenges.”
Frazier continued, “We are driving continued momentum across our
business and expect our current product portfolio to deliver strong
growth over the next five years. Our science-led approach to
R&D, managed by our outstanding team of scientists globally,
continues to deliver a broad set of pipeline opportunities from
discovery to clinical development that give us confidence in our
sustainable growth prospects and demonstrate that we are well
positioned to continue our success into the future.”
During the event, members of Merck’s leadership team will
outline the company’s strategic priorities to generate value for
patients and shareholders. These include how Merck will:
- Unlock Global Commercial Potential of the Portfolio. In
recent years, the company has executed on its opportunities around
the world, leveraging its global strength and scale. The company
expects to continue its momentum and deliver strong revenue growth
every year in the next five years, including 2023 – the year of
greatest anticipated impact of the JANUVIA LOE – driven by demand
for its portfolio of innovative products across oncology, vaccines,
hospital acute care and animal health.
- Drive Margin Expansion While Investing in the Pipeline.
Merck will continue to evolve its operating model to build a
leaner, more efficient organization. These efforts are aimed at
maximizing revenue potential and delivering meaningful operating
margin expansion, while allowing the company to invest in the most
value-creating growth opportunities.
- Advance a Robust Pipeline to Sustain Leadership Over the
Next Decade. The company has a broad portfolio of innovative
assets that will enable it to build upon its leadership in oncology
and vaccines. In addition, the company is making investments in
infectious diseases, cardiovascular medicine and other areas of
high unmet need.
- Deliver Next Generation of Scientific Breakthroughs.
Merck’s scientists are leveraging knowledge gained from experience
with the company's leading immuno-oncology franchise to advance
their understanding of human biology in many other areas of
research. The company’s strengthened scientific leadership and new
cutting-edge discovery research hubs located in key biopharma
research communities will help deliver important new clinical
candidates that will benefit patients over the next decade and
beyond.
2019 Investor Day Presenters
Investor Day will feature presentations from the following Merck
executives:
- Ken Frazier, Chairman and Chief Executive Officer
- Rob Davis, Executive Vice President, Global Services,
and Chief Financial Officer
- Frank Clyburn, Executive Vice President, Chief
Commercial Officer
- Rick DeLuca, Executive Vice President and President,
Merck Animal Health
- Dr. Roger Perlmutter, Executive Vice President and
President, Merck Research Laboratories
- Mike Nally, Executive Vice President, Chief Marketing
Officer
- Dr. Roy Baynes, Senior Vice President, Clinical
Development, and Chief Medical Officer
- Dr. Dean Li, Senior Vice President, Discovery Sciences
and Translational Medicine
- Dr. Fiona Marshall, Vice President, Neuroscience
Discovery, and Head of Discovery Research, MRL UK
- Dr. Daria Hazuda, Vice President, Infectious Diseases
Discovery and Chief Scientific Officer, MRL Exploratory Science
Center Cambridge
The full biographies of the speakers can be found at
www.merck.com/investorday.
Webcast Details
Merck invites shareholders, the investment community and the
media to listen to a live webcast of the Investor Day event today
from 8:30 am to 12:00 pm EDT. To join the webcast and view related
materials, including presentations and speaker biographies, please
visit the Merck investor relations website at
www.merck.com/investorday. A replay and transcript will be
available shortly after the completion of the live webcast.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us on Twitter, Facebook,
Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2018
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190620005155/en/
Media: Jenn Mauer (908) 740-1801 Jess Fine (908) 740-1707 Pamela
Eisele (267) 305-3558 Investors: Teri Loxam (908) 740-1986 Peter
Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024